{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.84","upperLimit":"90.57","value":"33.3"},{"groupId":"OG001","lowerLimit":"0.28","upperLimit":"48.25","value":"11.1"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"26.46","value":"0"},{"groupId":"OG003","lowerLimit":"0.36","upperLimit":"57.87","value":"14.3"},{"groupId":"OG004","lowerLimit":"0.51","upperLimit":"71.64","value":"20.0"},{"groupId":"OG005","lowerLimit":"0.00","upperLimit":"84.19","value":"0"},{"groupId":"OG006","lowerLimit":"0.00","upperLimit":"70.76","value":"0"},{"groupId":"OG007","lowerLimit":"0.42","upperLimit":"64.12","value":"16.7"},{"groupId":"OG008","lowerLimit":"0.18","upperLimit":"33.87","value":"7.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"14"}],"units":"Participants"}],"description":"CR+CRh+CRi rate was defined as percentage of participants with CR, CRh, or CRi. CR: Morphologic CR \\<5% blasts; Absolute neutrophil count (ANC) \\>1000/μL; Platelets ≥100,000/μL; Participant independent of transfusions; No residual evidence of active extramedullary disease; MRD+ or unknown. CRh: Met requirements for CR except ANC \\>500/μL and platelets \\>50,000/μL. CRi: Met requirements for CR except either ANC \\<1000/μL or platelets \\<100,000/μL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Dose Escalation - Schedule A: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.045 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG001","title":"Dose Escalation - Schedule A: IMGN632 0.045 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.09 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG002","title":"Dose Escalation - Schedule A: IMGN632 0.09 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.18 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG003","title":"Dose Escalation - Schedule A: IMGN632 0.18 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.3 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG004","title":"Dose Escalation - Schedule A: IMGN632 0.3 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.45 mg/kg via IV infusion on Day 1 of each 21-day cycle.","id":"OG005","title":"Dose Escalation - Schedule A: IMGN632 0.45 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.015 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG006","title":"Dose Escalation - Schedule B: IMGN632 0.015 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.03 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG007","title":"Dose Escalation - Schedule B: IMGN632 0.03 mg/kg"},{"description":"Participants received IMGN632 at a dose of 0.06 mg/kg via IV infusion on Days 1, 4, and 8 of each 21-day cycle.","id":"OG008","title":"Dose Escalation - Schedule B: IMGN632 0.06 mg/kg"}],"paramType":"NUMBER","populationDescription":"mITT Population included all participants who were eligible based on the screening criteria and who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = participants with AML in Dose Escalation Phase only.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"Dose Escalation Phase: CR+CRh+CRi Rate, As Assessed by Investigator in Participants With AML","type":"SECONDARY","unitOfMeasure":"percentage of participants"}